Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
Protocol ID
1367.1
Disease (Sub Disease)
Non malignant Skin Cancer
Kidney Cancer
Kidney Cancer
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Relapse/Refractory
Sponsor
Boehringer Ingelheim
Links
Trial Status
Completed
Trial Close Date
23/11/2021
Study Type
Treatment
Phase
Phase 1
Age Eligibility
18 Years and older
International registry ID's
NCT02516553
| Study Title | An open label Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit |
|---|---|
| Protocol ID | 1367.1 |
| Disease (Sub Disease) | Non malignant Skin Cancer Kidney Cancer |
| Diagnosis Stage | New Diagnosis Relapse/Refractory |
| Sponsor | Boehringer Ingelheim |
| Links | https://clinicaltrials.gov/ct2/show/NCT02516553 |
| Trial Status | Completed |
| Trial Open Date | 09/12/2020 |
| Trial Close Date | 23/11/2021 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 18 Years and older |
| International registry ID's | NCT02516553 |